Compile Data Set for Download or QSAR
Report error Found 304 Enz. Inhib. hit(s) with all data for entry = 8622
LigandPNGBDBM292984(US10105367, Example 270 | US10376514, Example 270)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292986(US10105367, Example 272 | 6-(4-Methoxybenzyl)-9-(2...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292991(US10105367, Example 277 | US10376514, Example 277)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM293001(US10105367, Example 287 | US10376514, Example 287)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292961(US10105367, Example 247 | US10376514, Example 247)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292967(US10105367, Example 253 | US10376514, Example 253)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM408830(US10376514, Example 266 | 9-(1-((2S,6R)-2,6-Dimeth...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292982(US10105367, Example 268 | US10376514, Example 268)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292939(US10105367, Example 225 | US10376514, Example 225)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292942(US10105367, Example 228 | US10376514, Example 228)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292943(US10105367, Example 229 | US10376514, Example 229)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM292960(US10105367, Example 246 | US10376514, Example 246)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289557(8-((Dimethylamino)methyl)-6-(4-methoxybenzyl)-9-me...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289558(8-((Cyclopropyl(methyl)amino)methyl)-6-(4-methoxyb...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289559(8-((4-Hydroxypiperidin-1-yl)methyl)-6-(4-methoxybe...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289560(8-((Benzyl(2-hydroxyethyl)amino)methyl)-6-(4-metho...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289551(8-(2-Oxa-7-azaspiro[3.5]nonan-7-ylmethyl)-6-(4-met...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289552(7-((6-(4-Methoxybenzyl)-5-oxo-5,6-dihydrothieno[3,...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289553(6-(4-Methoxybenzyl)-8-(1-methyl-3-(trifluoromethyl...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289556(6-(4-Methoxybenzyl)-9-methyl-8-(morpholinomethyl)t...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289547(6-(4-Methoxybenzyl)-8-((4-(methylsulfonyl)piperazi...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289548(8-(2,2-Dimethylmorpholino)methyl)-6-(4-methoxybenz...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289549(8-(2-Oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl)-6-(...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289550(8-(7-Oxa-2-azaspiro[3.5]nonan-2-ylmethyl)-6-(4-met...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289541(8-((1,4-Oxazepan-4-yl)methyl)-6-(4-methoxybenzyl)t...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289543(6-(4-Methoxybenzyl)-8-(morpholinomethyl)thieno[3,2...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289545(8-(((2S,6R)-2,6-Dimethylmorpholino)methyl)-6-(4-me...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289546(8-((4-Ethyl-3-oxopiperazin-1-yl)methyl)-6-(4-metho...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289574(6-(4-Methoxybenzyl)-9-methyl-8-((4-methylpiperazin...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289575(6-(4-Methoxybenzyl)-9-methyl-8-((4-(methylsulfonyl...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289576(8-((4-Isopropylpiperazin-1-yl)methyl)-6-(4-methoxy...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289577(8-(2-Oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl)-6-(...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289570((S)-6-(4-Methoxybenzyl)-8-((2-(methoxymethyl)pyrro...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289571(6-(4-Methoxybenzyl)-9-methyl-8-((methyl((tetrahydr...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289572(2-(((6-(4-Methoxybenzyl)-9-methyl-5-oxo-5,6-dihydr...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289573(8-((1,4-Oxazepan-4-yl)methyl)-6-(4-methoxybenzyl)-...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289566(6-(4-Methoxybenzyl)-9-methyl-8-((methyl((tetrahydr...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289567(8-(((2S,6R)-2,6-Dimethylmorpholino)methyl)-6-(4-me...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289568(8-(Isoindolin-2-ylmethyl)-6-(4-methoxybenzyl)-9-me...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289569(8-((Cyclopropylamino)methyl)-6-(4-methoxybenzyl)-9...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289562(6-(4-Methoxybenzyl)-9-methyl-8-((((3-methyloxetan-...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289563(8-((4-Acetylpiperazin-1-yl)methyl)-6-(4-methoxyben...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289564(6-(4-Methoxybenzyl)-9-methyl-8-(((pyridin-3-ylmeth...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289565(6-(4-Methoxybenzyl)-9-methyl-8-((3-oxopiperazin-1-...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289617(6-(4-Chlorobenzyl)-9-((tetrahydro-2H-pyran-4-yl)me...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289618(6-(4-Chlorobenzyl)-9-(oxetan-3-yl)-8,9,10,11-tetra...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289620(6-(4-Methoxybenzyl)-9-((5-methyl-1,3,4-thiadiazol-...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289621(6-(4-Methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)m...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
LigandPNGBDBM289587((S)-8-((Hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)me...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

LigandPNGBDBM289592(tert-Butyl 6-(4-methoxybenzyl)-5-oxo-5,6,10,11-tet...)
Affinity DataIC50: 100nMAssay Description:The selectivity of compounds of the present invention was determined using a panel of recombinant human PDEs and an in vitro enzymatic assay (BPS Bio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

Displayed 1 to 50 (of 304 total ) | Next | Last >>
Jump to: